June 26, 2024
Haleon Sells Nicotine Replacement Therapy Business to Dr. Reddy’s for $630 Million
Haleon, Dr. Reddy’s, nicotine replacement therapy, business sale, $630 million
Sanofi Seeks Private Equity Bids for $20 Billion Consumer Health Division
Sanofi, Consumer Health, Private Equity, Bids, $20 Billion
CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests
CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing
Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development
Arrowhead Pharmaceuticals, cardiometabolic drug, plozasiran, zodasiran, RNAi therapies, cardiovascular disease, triglycerides, LDL cholesterol
Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership
Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership
Curie.Bio Raises $380M to Support Early-Stage Biotechs
Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg
Formation Bio Secures $372M Megaround to In-License Over 10 Drugs
Formation Bio, Megaround, In-License, Drugs, Biotech, AI-Focused
Wave Life Sciences Achieves Breakthrough in Huntington’s Disease Treatment with WVE-003, Eyes Accelerated Approval
Wave Life Sciences, Huntington’s disease, WVE-003, Phase Ib/IIa study, accelerated approval, mutant huntingtin protein, allele-selective silencing, RNA medicine
Sarepta Therapeutics: Next Steps After Full FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Sarepta Therapeutics, Duchenne muscular dystrophy, gene therapy, FDA approval, Elevidys, microdystrophin, ambulatory patients, non-ambulatory patients, pipeline development, rare diseases, genetic medicine.